P

Assignee

OMEROS CORP

US77 patents

Top patents by PatentIndex Score

US6645168B2Nov 11, 2003

Arthroscopic irrigation solution and method for inhibition of pain and inflammation

OMEROS CORP78 citations99
US6420432B2Jul 16, 2002

Surgical irrigation solution and method for inhibition of pain and inflammation

OMEROS CORP83 citations99
US6740100B2May 25, 2004

Tendon repair using adhesive

OMEROS CORP124 citations98
US7973068B2Jul 5, 2011

Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation

OMEROS CORP71 citations97
US7067144B2Jun 27, 2006

Compositions and methods for systemic inhibition of cartilage degradation

OMEROS CORP100 citations97
US7919094B2Apr 5, 2011

Methods for treating conditions associated with MASP-2 dependent complement activation

OMEROS CORP86 citations95
US6492332B1Dec 10, 2002

Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation

OMEROS CORP126 citations95
US9644035B2May 9, 2017

Methods for treating conditions associated with MASP-2 dependent complement activation

OMEROS CORP18 citations92
US9399040B2Jul 26, 2016

Ophthalmologic irrigation solutions and method

OMEROS CORP11 citations92
US9278101B2Mar 8, 2016

Ophthalmologic irrigation solutions and method

OMEROS CORP14 citations92
US9066856B2Jun 30, 2015

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

OMEROS CORP15 citations92
US8343970B2Jan 1, 2013

PDE10 inhibitors and related compositions and methods

OMEROS CORP12 citations92
US6413961B1Jul 2, 2002

Irrigation solution and method for inhibition of pain and inflammation

OMEROS CORP51 citations92
US9475885B2Oct 25, 2016

Compositions for inhibiting MASP-2 dependent complement activation

OMEROS CORP15 citations91
US7091181B2Aug 15, 2006

Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors

OMEROS CORP22 citations90
US7786139B2Aug 31, 2010

PDE10 inhibitors and related compositions and methods

OMEROS CORP16 citations89
US9855246B2Jan 2, 2018

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

OMEROS CORP9 citations84
US9585895B2Mar 7, 2017

Ophthalmologic irrigation solutions and method

OMEROS CORP5 citations84
US9486406B2Nov 8, 2016

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

OMEROS CORP10 citations84
US9434707B2Sep 6, 2016

PDE10 inhibitors and related compositions and methods

OMEROS CORP3 citations83
US8685975B2Apr 1, 2014

PDE10 inhibitors and related compositions and methods

OMEROS CORP8 citations83
US8377930B2Feb 19, 2013

PDE10 inhibitors and related compositions and methods

OMEROS CORP11 citations83
US9220715B2Dec 29, 2015

Treatment of addiction and impulse-control disorders using PDE7 inhibitors

OMEROS CORP5 citations82
US7297348B2Nov 20, 2007

Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from

OMEROS CORP18 citations82
US10059776B2Aug 28, 2018

Methods for treating conditions associated with MASP-2 dependent complement activation

OMEROS CORP2 citations73
US9102643B2Aug 11, 2015

PDE10 inhibitors and related compositions and methods

OMEROS CORP3 citations73
US12030853B2Jul 9, 2024

MASP-2 inhibitors and methods of use

OMEROS CORP4 citations72
US11883493B2Jan 30, 2024

Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

OMEROS CORP1 citations72
US11661418B2May 30, 2023

MASP-2 inhibitors and methods of use

OMEROS CORP4 citations72
US11207275B2Dec 28, 2021

Treatment of addiction and impulse-control disorders using PDE7 inhibitors

OMEROS CORP2 citations72
US11027015B2Jun 8, 2021

Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

OMEROS CORP1 citations72
US10745274B1Aug 18, 2020

Nucleic acids encoding antibodies specifically binding to MASP-3

OMEROS CORP2 citations72
US10639369B2May 5, 2020

Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

OMEROS CORP2 citations72
US11584714B2Feb 21, 2023

MASP-2 inhibitors and methods of use

OMEROS CORP5 citations71
US10870708B2Dec 22, 2020

Methods for inhibiting angiogenesis in a subject in need thereof

OMEROS CORP3 citations71
US9677070B2Jun 13, 2017

Composition and method for diversification of target sequences

OMEROS CORP6 citations71
US11807641B2Nov 7, 2023

MASP-2 inhibitors and methods of use

OMEROS CORP2 citations70
US11628217B2Apr 18, 2023

Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods

OMEROS CORP2 citations70
US11453709B2Sep 27, 2022

Chimeric inhibitor molecules of complement activation

OMEROS CORP1 citations69
US11241420B2Feb 8, 2022

Compositions and methods for prophylaxis and treatment of addictions

OMEROS CORP2 citations69
US10064850B2Sep 4, 2018

Compositions and methods for prophylaxis and treatment of addictions

OMEROS CORP2 citations69
US9493447B2Nov 15, 2016

Optically active PDE10 inhibitor

OMEROS CORP3 citations68
US10292374B2May 21, 2019

G protein coupled receptor 85 and SREB3 knockout mice and uses thereof

OMEROS CORP1 citations67
US11896621B2Feb 13, 2024

Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant

OMEROS CORP0 citations62
US11884742B2Jan 30, 2024

Methods for treating conditions associated with MASP-2 dependent complement activation

OMEROS CORP0 citations62
US11525011B2Dec 13, 2022

Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome

OMEROS CORP1 citations62
US11013772B2May 25, 2021

Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant

OMEROS CORP0 citations62
US11613589B2Mar 28, 2023

Compositions for inhibiting MASP-2 dependent complement activation

OMEROS CORP0 citations61
US11464785B2Oct 11, 2022

Treatment of addiction and impulse-control disorders using PDE7 inhibitors

OMEROS CORP0 citations61
US12486278B2Dec 2, 2025

MASP-2 inhibitors and methods of use

OMEROS CORP0 citations60

Showing the top 50 of 77 patents by PatentIndex Score.